Free Trial
NASDAQ:MGTX

MeiraGTx Q3 2023 Earnings Report

MeiraGTx logo
$6.58 +0.03 (+0.46%)
As of 11:12 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MeiraGTx EPS Results

Actual EPS
-$0.74
Consensus EPS
-$0.63
Beat/Miss
Missed by -$0.11
One Year Ago EPS
N/A

MeiraGTx Revenue Results

Actual Revenue
$5.10 million
Expected Revenue
$3.54 million
Beat/Miss
Beat by +$1.56 million
YoY Revenue Growth
N/A

MeiraGTx Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 14, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

MeiraGTx's Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

MeiraGTx Earnings Headlines

MeiraGTx Holdings: Gaining Regulatory Focus
Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
MeiraGTx price target raised to $13 from $11 at RBC Capital
Meiragtx Holdings (MGTX) Gets a Buy from Evercore ISI
See More MeiraGTx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MeiraGTx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MeiraGTx and other key companies, straight to your email.

About MeiraGTx

MeiraGTx (NASDAQ:MGTX), a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

View MeiraGTx Profile

More Earnings Resources from MarketBeat